BPC-157 Update: HHS Policy, Human Evidence & WADA Status

BPC-157 is back in the compounding-policy conversation—but what does HHS's new notice actually change, and what does the human evidence show? In this revisit, John Garrett looks at BPC-157's proposed biology, the three small published human reports, new clinical-trial registry entries, the FDA advisory committee's recommendation, and HHS's October 30 interim enforcement-discretion policy. The published human record remains small and very low certainty. For BPC-157, the HHS policy identifies the acetate form and specified dosage forms under limited Section 503A circumstances. It is conditional and interim; it does not make BPC-157 FDA-approved, add it to the 503A Bulks List, or establish that it works. We also explain why the anti-doping rules are a separate question. This episode is for informational purposes only and is not medical advice. Research and policy details were checked October 30, 2026; verify current status before publication.